Burkitt-Like Lymphoma with 11q Aberration
NCI Definition: A molecularly distinct B-cell lymphoma reminiscent of Burkitt lymphoma. It is characterized by the absence of MYC translocation and the presence of chromosome 11q aberrations. 
There is 1 clinical trial for Burkitt-like lymphoma with 11q aberration, of which 1 is open and 0 are completed or closed. Of the trial that contains Burkitt-like lymphoma with 11q aberration as an inclusion criterion, 1 is phase 2 (1 open).
Nivolumab is the most common intervention in Burkitt-like lymphoma with 11q aberration clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.